Want to see ALPS full AI Analyst Report?
Top Page
ALPS Group
(NASDAQ:ALPS)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.33
▼(-21.67% Downside)
Action:N/A
Date:09/17/26
The score is primarily weighed down by weak financial performance (persistent losses, ongoing cash burn, and negative equity), which increases funding and dilution risk. Technicals are mixed-to-weak with the stock below key longer-term moving averages, while valuation is difficult to support due to negative earnings and no dividend yield.
Positive Factors
Strong Revenue Rebound
The 44% revenue increase demonstrates meaningful commercial expansion across the company’s therapy, testing, laboratory, and aesthetics activities. If the broader demand trend persists, higher scale can support platform investment, customer reach, and improved operating leverage over the next several quarters.
Negative Factors
Persistent Unprofitability
Deeply negative margins and continuing EBIT and EBITDA losses show that revenue growth has not yet translated into sustainable earnings. The company therefore remains dependent on successfully scaling operations or securing additional capital before its business model can generate durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Rebound
The 44% revenue increase demonstrates meaningful commercial expansion across the company’s therapy, testing, laboratory, and aesthetics activities. If the broader demand trend persists, higher scale can support platform investment, customer reach, and improved operating leverage over the next several quarters.
Read all positive factors
ALPS Group (ALPS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$61.45M
Dividend Yield8.44%
Average Volume (3M)56.56K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees93
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding166,400,310
10 Day Avg. Volume49,610
30 Day Avg. Volume56,560
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-55.53
Price to Sales (P/S)33.44
P/FCF Ratio-61.70
Enterprise Value/Market Cap1.98M
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-80.73M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ALPS Group Business Overview & Revenue Model
Company Description
Alps Group Inc. operates as a comprehensive biotechnology firm, delivering a wide array of services ranging from groundbreaking research and development to direct medical care and health optimization initiatives, with a primary focus on cutting-ed...
How the Company Makes Money
ALPS makes money primarily by selling electronic components and integrated modules to business customers (OEMs and tier suppliers) that incorporate these parts into finished products such as vehicles, consumer electronics, and industrial devices. ...
ALPS Group Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 4.86M | 3.37M | 2.40M | 3.59M | 0.00 |
| Gross Profit | 0.00 | 1.56M | 1.30M | 598.93K | 1.98M | 0.00 |
| EBITDA | -1.51M | -901.36K | -1.35M | -1.45M | 363.17K | -119.63K |
| Net Income | -2.73M | -2.01M | -2.51M | -2.30M | -729.16K | -119.63K |
Balance Sheet | ||||||
| Total Assets | 1.74M | 6.97M | 7.13M | 6.70M | 119.22M | 117.96M |
| Cash, Cash Equivalents and Short-Term Investments | 357.73K | 607.47K | 318.93K | 460.47K | 81.76K | 812.23K |
| Total Debt | 5.91M | 559.27K | 6.93M | 507.57K | 0.00 | 0.00 |
| Total Liabilities | 12.97M | 10.20M | 8.25M | 5.25M | 4.84M | 4.37M |
| Stockholders Equity | -11.23M | -2.92M | -888.56K | 1.57M | 113.81M | 113.59M |
Cash Flow | ||||||
| Free Cash Flow | -962.42K | -2.63M | -1.69M | -1.59M | -388.04K | -324.87K |
| Operating Cash Flow | -962.42K | -2.58M | -1.61M | -1.37M | -113.57K | -324.87K |
| Investing Cash Flow | 28.77M | 26.60M | -100.06K | -1.71M | -288.29K | -116.72M |
| Financing Cash Flow | -27.51M | -24.39M | 1.87M | 3.28M | 212.92K | 117.86M |
ALPS Group Technical Analysis
Negative
0.42
Price Trends
0.38
Negative
0.50
Negative
0.73
Negative
Market Momentum
>-0.01
Positive
42.87
Neutral
43.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALPS, the sentiment is Negative. The current price of 0.42 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.38, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.87 is Neutral, neither overbought nor oversold. The STOCH value of 43.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALPS.
ALPS Group Risk Analysis
ALPS Group disclosed 77 risk factors in its most recent earnings report. ALPS Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ALPS Group Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | $70.48M | -3.26 | -161.58% | ― | ― | 23.02% | |
45 Neutral | $54.60M | -1.23 | -71.71% | ― | ― | 73.44% | |
44 Neutral | $71.00M | -1.92 | -211.15% | ― | ― | -7.28% | |
43 Neutral | $49.93M | -0.68 | -685.96% | ― | ― | 11.96% | |
42 Neutral | $92.65M | -8.09 | 44.67% | ― | -96.72% | -253.97% | |
41 Neutral | $61.45M | -0.50 | 30.70% | 8.44% | ― | ― |
* General Sector Average
ALPS
ALPS Group
0.37
-14.63
-97.54%
ATRA
Atara Biotherapeutics
9.23
-5.09
-35.54%
ANVS
Annovis Bio
1.17
-0.53
-31.18%
KLRS
Kalaris Therapeutics
2.50
-1.95
-43.82%
GANX
Gain Therapeutics
1.62
-0.36
-18.02%
MAIA
MAIA Biotechnology, Inc.
1.15
-0.37
-24.34%
ALPS Group Corporate Events
Alps Group Posts 44% Revenue Growth in FY2026 as Nasdaq‑Listed Biotech Sharpens Precision Medicine Focus
Aug 7, 2026
Alps Group Inc, an integrated biotechnology platform based in Kuala Lumpur, generates revenue from cellular therapies, medical testing, aesthetics services and healthcare products to support its pipeline in precision medicine. Operating across cel...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.